BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu C, Xue Y, Liu M, Wang Y, Liu Z, Diao H, Chen L. Orexins increase the firing activity of nigral dopaminergic neurons and participate in motor control in rats. J Neurochem 2018;147:380-94. [DOI: 10.1111/jnc.14568] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Chen AQ, Xue Y, Liu MF, Liu C, Liu YH, Pan YP, Diao HL, Chen L. Orexins alleviate motor deficits via increasing firing activity of pallidal neurons in a mouse model of Parkinson's disease. Am J Physiol Cell Physiol 2019;317:C800-12. [PMID: 31365289 DOI: 10.1152/ajpcell.00125.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
2 Orlowska-Feuer P, Smyk MK, Palus-Chramiec K, Dyl K, Lewandowski MH. Orexin A as a modulator of dorsal lateral geniculate neuronal activity: a comprehensive electrophysiological study on adult rats. Sci Rep 2019;9:16729. [PMID: 31723155 DOI: 10.1038/s41598-019-53012-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Xue B, Li C, Chang X, Jiang H, Shi L, Xie J. Ghrelin Reduces A-Type Potassium Currents in Dopaminergic Nigral Neurons via the PLC/PKCδ Pathway. Neurosci Bull 2020;36:947-50. [PMID: 32388709 DOI: 10.1007/s12264-020-00508-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Berhe DF, Gebre AK, Assefa BT. Orexins role in neurodegenerative diseases: From pathogenesis to treatment. Pharmacol Biochem Behav 2020;194:172929. [PMID: 32315694 DOI: 10.1016/j.pbb.2020.172929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Bian K, Liu C, Wang Y, Xue Y, Chen L. Orexin-B exerts excitatory effects on nigral dopaminergic neurons and alleviates motor disorders in MPTP parkinsonian mice. Neurosci Lett 2021;765:136291. [PMID: 34666119 DOI: 10.1016/j.neulet.2021.136291] [Reference Citation Analysis]
6 Liu MF, Xue Y, Liu C, Liu YH, Diao HL, Wang Y, Pan YP, Chen L. Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease. Front Neurosci 2018;12:835. [PMID: 30524223 DOI: 10.3389/fnins.2018.00835] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
7 Wang Q, Cao F, Wu Y. Orexinergic System in Neurodegenerative Diseases. Front Aging Neurosci 2021;13:713201. [PMID: 34483883 DOI: 10.3389/fnagi.2021.713201] [Reference Citation Analysis]
8 Seigneur E, de Lecea L. Hypocretin (Orexin) Replacement Therapies. Medicine in Drug Discovery 2020;8:100070. [DOI: 10.1016/j.medidd.2020.100070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Liu MF, Xue Y, Liu C, Liu YH, Diao HL, Wang Y, Pan YP, Chen L. Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease. Front Neurosci 2018;12:835. [PMID: 30524223 DOI: 10.3389/fnins.2018.00835] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Bi M, Du X, Jiao Q, Liu Z, Jiang H. α-Synuclein Regulates Iron Homeostasis via Preventing Parkin-Mediated DMT1 Ubiquitylation in Parkinson's Disease Models. ACS Chem Neurosci 2020;11:1682-91. [PMID: 32379419 DOI: 10.1021/acschemneuro.0c00196] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]